Objective: To determine the actual use of 'statin' therapy for primary and secondary prevention and the potential effect of using the Sheffield Results: A total of 1500 patients were reviewed of which 416 (27.7%) had experienced at least one clinical manifestation of atherosclerotic cardiovascular disease (CVD) and 392 (94%) of these had a total cholesterol measured of whom 298 (76%) had a total cholesterol Ͼ5.5 mmol/l. Only 11.2% of eligible patients were actually receiving lipid-lowering treatment for secondary
Introduction
The importance of lowering cholesterol with 'statins' for the secondary prevention of cardiovascular disease is now well documented. 1, 2 Patients suitable for secondary prevention are readily identifiable. In such patients appropriate cholesterol-lowering therapy appears to be cost effective 3 with an absolute benefit from treatment such that fewer than 10 patients need to be treated for 1 year to prevent one 'event'. The results of the recently published Cholesterol and Recurrent Events Trial (CARE) 2 indicate that patients with myocardial infarction may benefit from lipid-lowering therapy with a statin, even if the cholesterol level is within an acceptable northern European limit (Ͻ5.3 mmol/l). The implication of this is that the majority of survivors of myocardial infarction will become candidates for statin therapy.
However, the benefit of cholesterol reduction for primary prevention is less clear. The best data comes from the West of Scotland Coronary Prevention Study (WOSCOPS) in which middle-aged men without symptomatic coronary artery disease were also shown to benefit from treatment with a statin. The relative benefits from statin were the same (about a 30% reduction in risk) as for secondary prevention, though the absolute benefit was much smaller (because of the smaller absolute risk). The cost to the Health Service of treating all with an elevated cholesterol appears to be prohibitive and attempts have been made to target patients at greatest risk. Those who stand to benefit most from primary prevention are the over 50s, those with ECG abnormalities, smokers, hypertensives, and diabetics. 4 This problem has been partially addressed by the publication of two risk assessment tables, the Sheffield Table for primary prevention of coronary heart disease 5, 6 and the New Zealand guidelines. Both tables acknowledge the importance of multiple risk factors when assessing cardiovascular risk in respect of primary prevention and both provide a reasonably user-friendly template for stratifying risk and for targeting lipid-lowering therapy with statins.
For the purpose of this study the Sheffield Table has two advantages. Firstly it predefines the level of coronary risk (3%) at which treatment should be initiated, and secondly the level of risk is high representing what many would consider to be the minimal level at which cholesterol-lowering treatment should be initiated.
We therefore assessed the potential impact of the Sheffield Table on the management of patients attending the Aberdeen Hypertension Clinic.
Patients and methods
The medical details of 1500 consecutive patients attending the Aberdeen Hypertension Clinic were recorded. Patients were classified as suitable for secondary prevention with statin treatment if they had a diagnosis of cardiovascular disease (myocardial infarction, angina), cerebrovascular disease (stroke, TIA), peripheral or reno-vascular disease, were under 71 years of age and had a cholesterol of у5.5 mmol/l. These criteria correspond to those used in the 4S study. The remaining patients were stratified for primary prevention with statin treatment using the Sheffield Table.
Results

Secondary prevention
Of 1500 patients, 416 (27.7%) had already experienced at least one clinical manifestation of atherosclerotic cardiovascular disease (CVD). Of these 392 (94%) had had a total cholesterol (TC) measured and of those 298 (76%) had a TC Ͼ5.5 mmol/l and thus might be considered suitable for lipid lowering with a statin.
However, only 44 (11.2%) patients were actually receiving lipid-lowering treatment.
Primary prevention
Of 1084 patients with no prior CVD, 97 (8.9%) were excluded because of age. Of the remaining 987, TC had been measured in 914 (92.6%). Using the Sheffield Table 638 (69.8%) patients had been tested unnecessarily. However, according to the table, 92 (9.3%) patients were eligible for statin therapy. Only six of the 92 patients were actually receiving treatment.
Discussion
The results of this study reveal that even in a consultant-led cardiovascular prevention clinic there is a massive discrepancy between optimal evidencebased management and the actual delivery of clinical care. We have identified that 72% and 9.3% of patients attending the Aberdeen Hypertension Clinic would be eligible for statin treatment for both secondary and primary prevention respectively. Although 96% of all patients who should have been considered for secondary prevention had a total cholesterol measurement performed, it is of concern that only 11.2% of these patients were actually receiving appropriate treatment. In the 4S and CARE studies patients selected for secondary prevention were either post-myocardial infarction or had angina. Our secondary prevention group was rather wider and included patients in whom statin therapy is not of proven value (eg, stroke and peripheral vascular disease). However, pending the results of ongoing studies, such as the MRC Heart Protection Study, this seemed a reasonable extrapolation.
Based on the 4S study we chose a cholesterol level of 5.5 mmol/l as the criteria for instigating lipid-lowering therapy. In the light of the CARE study this value may now be considered conservative. If a lower level of cholesterol had been chosen for intervention the shortfall in administration of statin therapy would have been even more striking. Use of the Sheffield Table identified a further cohort of patients, forming 6.1% of the screened population, who might benefit from statin treatment for primary prevention. The level of risk identified by using the Sheffield Table is relatively high (3% annual event rate) but it is clear that even in a specialist consultant-led clinic the vast majority of patients are not yet receiving appropriate evidence-based care according to this conservative approach. These findings have especially significant implications for health care strategy in Scotland, a country with a high prevalence of cardiovascular disease. It is well documented that effective treatments often takes many years to become accepted as standard therapy. This was well-illustrated by the length of time taken for the introduction of fibrinolytic therapy for myocardial infarction. The possible reasons for such an obvious delay in the introduction of statins in this study are unclear but include a circumspect approach to new drugs, a lack of awareness of current trial results, reluctance on the part of prescribers and patients to embark upon polypharmacy and perceived drug costs.
Although the reasons for a shortfall of this magnitude in the delivery of effective treatment are not yet clear these data are both robust and of considerable importance to the clinician and patient alike. The Sheffield Table allows coronary risk to be quantified on the basis of risk factors rather than cholesterol level per se. This fact is reflected in our observation that if the table is used as a basis for decision making, a significant population (70%) of cholesterol measurements in the primary prevention group may be unnecessary. If nothing else this should make a useful contribution to offsetting the cost of statin therapy.
We used the Sheffield Table for this audit because it represents a highly conservative approach to cholesterol lowering, targeting a high risk population in whom there is no doubt that statin therapy would be of benefit. For this reason the shortfall we observed in our own practice is of even more concern. If a CHD risk level of 2% as recommended by the European Society of Cardiology, 7 or 1% as used in the WOSCOPS trial had been used then the proportion of patients under-treated would have been significantly greater. The Sheffield Table has been criticised 8, 9 for focusing solely on a very high risk patient group, for using total cholesterol rather than the ratio of total to high density lipoprotein (HDL) cholesterol, for underestimating the risk to the diabetic population, for oversimplification and for practising agism. While the Sheffield Table would undoubtedly benefit from refinement such as the inclusion of HDL data and weighting for potential life-years gained it at least offers a method of coronary risk assessment that is readily applicable in the clinic. The debate on these issues is likely to continue but we believe that the implementation of the current table is a clinically useful exercise. In our experience it is not possible to make rational or accurate estimates of risk, and informed decisions about lipid-lowering treatment in individual patients without some form of table or similar device. It is clear that to supply appropriate care the use of a CHD risk assessment algorithm is essential. Whether one uses this to target a CHD risk of 1, 2 or 3% or to target patients who will gain the maximum number of potential life-years is not so clear.
